Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

KM Biologics President Nagasato

Toshiaki Nagasato, president of KM Biologics Co., gives an interview to Kyodo News in the southwestern Japan city of Kumamoto on Nov. 7, 2022. The Japanese pharmaceuticals company is developing a domestic COVID-19 vaccine.

E

KM Biologics President Nagasato

Toshiaki Nagasato, president of KM Biologics Co., gives an interview to Kyodo News in the southwestern Japan city of Kumamoto on Nov. 7, 2022. The Japanese pharmaceuticals company is developing a domestic COVID-19 vaccine.

E

World Vaccine Congress Europe 2022 held in Spain's Barcelona

STORY: World Vaccine Congress Europe 2022 held in Spain's Barcelona DATELINE: Oct. 14, 2022 LENGTH: 00:01:59 LOCATION: Madrid CATEGORY: HEALTH SHOTLIST: 1. various of the congress 2. various of pharmaceutical entrepreneurs, academics, scientists and industry experts accessing the congress 3. SOUNDBITE 1 (English): WING-YUN CHEUNG, General Manager of the World Vaccine Congress 4. SOUNDBITE 2 (English): PIERRE MORGON, Senior Vice President of International Business at CanSino Biologics 5. various of speakers delivering talks STORYLINE: The 23rd edition of the World Vaccine Congress Europe 2022 ended its four-day session on Friday in Barcelona, Spain. The event brought together scientists, academics, pharmaceutical, biotech, life science and healthcare firms around the world to explore the latest technology and progress in the area of vaccines. SOUNDBITE 1 (English): WING-YUN CHEUNG, General Manager of the World Vaccine Congress "We want to bring the right scientists, funders, government agencies, and ultim

E

How China's Jiangsu promotes industrial modernization

STORY: How China's Jiangsu promotes industrial modernization DATELINE: Sept. 9, 2022 LENGTH: 0:02:00 LOCATION: NANJING, China CATEGORY: ECONOMY SHOTLIST: 1. various of Jiangsu 2. SOUNDBITE 1 (Chinese): KANG ZAIXIANG, Technician, Xuzhou Construction Machinery Group (XCMG) 3. SOUNDBITE 2 (Chinese): ZHANG XINKUI, Assistant Director of Structural Factory in Xuzhou Construction Machinery Group (XCMG) 4. SOUNDBITE 3 (Chinese): CHEN BINGLIANG, Chief scientist of Innovent Biologics STORYLINE: In the past 10 years, east China's Jiangsu Province has been promoting the modernization of its industries. In 2021, the value-added output of Jiangsu's manufacturing industry exceeded 4 trillion yuan (579 billion U.S. dollars), making up 35.8 percent of its GDP, the highest ratio compared with other provincial-level regions in China. The province now boasts 16 advanced manufacturing clusters and 50 key industrial chains, including industries like construction machinery and wind power equipment. And it has been the pacesett

E

Xinhua Headlines: CPC seeks national rejuvenation by following Chinese path to modernization

(220729) -- BEIJING, July 29, 2022 (Xinhua) -- A technician works during a test run of the "fill and finish" process for CanSino vaccines at Solution Biologics factory in Kuala Lumpur, Malaysia, Sept. 8, 2021. Chinese company CanSino Biologics has helped Malaysia cross a milestone in vaccine manufacturing, by transferring technology to enable the local "fill and finish" of the COVID-19 vaccines based on the adenovirus platform. (Photo by Chong Voon Chung/Xinhua)

E

GLOBALink | Biomedical firms whitelisted in Shanghai resume work

STORY: Biomedical firms whitelisted in Shanghai resume work DATELINE: May 25, 2022 LENGTH: 0:01:04 LOCATION: SHANGHAI, China CATEGORY: HEALTH SHOTLIST: 1. Fosun Kite Biotechnology Co., Ltd. 2. CanSino (Shanghai) Biological Research Co., Ltd. 3. SOUNDBITE 1 (Chinese): LIU QUAN, Associate director, CanSino (Shanghai) Biological Research Co., Ltd. 4. SOUNDBITE 2 (Chinese): WANG HAOMENG, Deputy general manager, CanSino (Shanghai) Biological Research Co., Ltd. STORYLINE: COVID-hit Shanghai has whitelisted some companies to support their resumption of work. Fosun Kite Biotechnology Co., Ltd. is among the first batch approved to resume operation. Production has fully restarted with 140 workers back to their positions. The factory produces Yescarta, a CAR-T therapy to treat certain types of large B-cell lymphoma. Shanghai subsidiary of Chinese vaccine developer CanSino Biologics Inc. has also resumed operation. The company gained approval to launch clinical trials for its experimental COVID-19 mRNA vaccine i

E

Domestic production of COVID-19 vaccine

Photo taken in the Kumamoto Prefecture city of Kikuchi, southwestern Japan, on Dec. 16, 2021, shows a COVID-19 vaccine production facility recently completed at a lab of Japanese pharmaceutical firm KM Biologics Co. The facility, which the Kumamoto Prefecture-based company unveiled to the media the same day to mark its completion, plans to start operation in April 2022 with annual production of 15 million shots.

E

Domestic production of COVID-19 vaccine

Photo taken in the Kumamoto Prefecture city of Kikuchi, southwestern Japan, on Dec. 16, 2021, shows a COVID-19 vaccine production facility recently completed at a lab of Japanese pharmaceutical firm KM Biologics Co. The facility, which the Kumamoto Prefecture-based company unveiled to the media the same day to mark its completion, plans to start operation in April 2022 with annual production of 15 million shots.

E

Domestic production of COVID-19 vaccine

Photo taken in the Kumamoto Prefecture city of Kikuchi, southwestern Japan, on Dec. 16, 2021, shows a COVID-19 vaccine production facility recently completed at a lab of Japanese pharmaceutical firm KM Biologics Co. The facility, which the Kumamoto Prefecture-based company unveiled to the media the same day to mark its completion, plans to start operation in April 2022 with annual production of 15 million shots.

E

Domestic production of COVID-19 vaccine

Photo taken in the Kumamoto Prefecture city of Kikuchi, southwestern Japan, on Dec. 16, 2021, shows a COVID-19 vaccine production facility recently completed at a lab of Japanese pharmaceutical firm KM Biologics Co. The facility, which the Kumamoto Prefecture-based company unveiled to the media the same day to mark its completion, plans to start operation in April 2022 with annual production of 15 million shots.

E

KM Biologics begins development of vaccine for novel coronavirus

KM Biologics (Kita Ward, Kumamoto City) has started to develop a vaccine for a new coronavirus infection. At a press conference held on April 25, President Nagasato said, "Our strength lies in the fact that we have skilled technicians and facilities from our days at the Research Institute for Chemotherapy and Serotherapy (KAKETSUKEN). As a member of the Meiji Group, we will do our utmost to expand this business. The new drug will be developed jointly with the National Institute of Infectious Diseases, the Institute of Medical Science of the University of Tokyo, and the National Institute of Biomedical Innovation, Health and Nutrition. The company will consider using its Kikuchi Research Center in Kikuchi City, Kumamoto Prefecture, and its Koshi Plant in Koshi City, Kumamoto Prefecture, which are capable of producing vaccines for 57 million new influenza cases. (Photo taken on May 25, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Centers for Disease Control and Prevention Director Dr. Rochelle Walensky speaks to Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration before a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on Tuesday, May 11, 2021 at the U.S. Capitol in Washington, D.C. Photo by Greg Nash/Pool/ABACAPRESS.COM

E

Senate Covid-19 Hearing - Washington

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, May 11, 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Covid-19 Hearing - Washington

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration answers a question during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on Tuesday, May 11, 2021 at the U.S. Capitol in Washington, DC, USA. Photo by Greg Nash/Pool/ABACAPRESS.COM

E

Senate Covid-19 Hearing - Washington

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases; Department of Health and Human Services Chief Science Officer for Covid Response David Kessler; Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration; and Centers for Disease Control and Prevention Director Dr. Rochelle Walensky are seen during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on Tuesday, May 11, 2021 at the U.S. Capitol in Washington, DC, USA. Photo by Greg Nash/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Anthony Fauci (L), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); Peter Marks (C-R), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), speak to prepare Democratic Senator from Washington Patty Murray (C-L) prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Anthony Fauci (L), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); Peter Marks (C-R), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), speak to prepare Democratic Senator from Washington Patty Murray (C-L) prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), speaks with and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; David Kessler (C-L), Chief Science Officer for COVID Response at the Department of Health and Human Services (HHS); Anthony Fauci (C-R), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prepare to testify before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; David Kessler (C-L), Chief Science Officer for COVID Response at the Department of Health and Human Services (HHS); Anthony Fauci (C-R), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prepare to testify before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Anthony Fauci (L), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); Peter Marks (C-R), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), speak to prepare Democratic Senator from Washington Patty Murray (C-L) prior to testifying before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Peter Marks (L), Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration FDA; David Kessler (C-L), Chief Science Officer for COVID Response at the Department of Health and Human Services (HHS); Anthony Fauci (C-R), Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH); and Rochelle Walensky (R), Director of the US Centers for Disease Control and Prevention (CDC), prepare to testify before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building in Washington, DC, USA, 11 May 2021. Photo by Jim Lo Scalzo/Pool/ABACAPRESS.COM

E

Senate Health, Education, Labor and Pensions Committee Hearing - Washington

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration gives an opening statement during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on Tuesday, May 11, 2021 at the U.S. Capitol in Washington, D.C. Photo by Greg Nash/Pool/ABACAPRESS.COM

E

Senate Committee Hearing On The Covid-19 Response - Washington

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration during a hearing with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee Hearing On The Covid-19 Response - Washington

Dr. Anthony Fauci, Director at the National Institute Of Allergy and Infectious Diseases, Dr. David Kessler, Chief Science Officer of the White House COVID-19 Response Team, Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, watch a Senator speak remotely during a hearing with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Hearing With The Senate Committee On Health, Education, Labor, And Pensions - DC

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, testifies during a Senate Health, Education, Labor and Pensions Committee hearing on the federal coronavirus response on Capitol Hill in Washington, Thursday, March 18, 2021. (AP Photo/Susan Walsh, Pool) Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Hearing With The Senate Committee On Health, Education, Labor, And Pensions - DC

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration listens during a hearing, with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee On Health, Education, Labor, And Pensions, Hearing On Covid-19 Response

Senator Richard Burr, R-N.C., Ranking Member of the Senate Committee on Health, Education, Labor, and Pensions, greets Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, before a hearing, with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee On Health, Education, Labor, And Pensions, Hearing On Covid-19 Response

From left to right: Dr. Anthony Fauci, Director at the National Institute Of Allergy and Infectious Diseases, Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration and Dr. Rochelle Walensky, Director for Centers for Disease Control and Prevention, and Dr. David Kessler, Chief Science Officer of the White House COVID-19 Response Team, speak to one another before a hearing, with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee On Health, Education, Labor, And Pensions, Hearing On Covid-19 Response

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration speaks with Dr. Rochelle Walensky, Director for Centers for Disease Control and Prevention, before the start of a hearing with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee On Health, Education, Labor, And Pensions, Hearing On Covid-19 Response

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration speaks with Dr. Rochelle Walensky, Director for Centers for Disease Control and Prevention, before the start of a hearing with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee On Health, Education, Labor, And Pensions, Hearing On Covid-19 Response

Dr. Anthony Fauci, Director at the National Institute Of Allergy and Infectious Diseases signs his Washington Nationals baseball cards for Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, before a hearing with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee On Health, Education, Labor, And Pensions, Hearing On Covid-19 Response

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration listens during a hearing, with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee On Health, Education, Labor, And Pensions, Hearing On Covid-19 Response

Dr. Anthony Fauci, Director at the National Institute Of Allergy and Infectious Diseases signs his Washington Nationals baseball cards for Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, before a hearing with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee On Health, Education, Labor, And Pensions, Hearing On Covid-19 Response

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration shows Washington Nationals baseball cards with the likeness of Dr. Anthony Fauci, Director at the National Institute Of Allergy and Infectious Diseases, at the start of a hearing, with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Hearing With The Senate Committee On Health, Education, Labor, And Pensions - DC

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, testifies during a Senate Health, Education, Labor and Pensions Committee hearing on the federal coronavirus response on Capitol Hill in Washington, Thursday, March 18, 2021. (AP Photo/Susan Walsh, Pool) Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Hearing With The Senate Committee On Health, Education, Labor, And Pensions - DC

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration speaks during a hearing, with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)

E

Senate Committee On Health, Education, Labor, And Pensions, Hearing On Covid-19 Response

From left to right: Dr. Anthony Fauci, Director at the National Institute Of Allergy and Infectious Diseases, Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration and Dr. David Kessler, Chief Science Officer of the White House COVID-19 Response Team, speak to one another before a hearing, with the Senate Committee on Health, Education, Labor, and Pensions, on the Covid-19 response, on Capitol Hill in Washington March 18th, 2021. Photo by Anna Moneymaker/Pool/ABACAPRESS.COM (Credit:Moneymaker Anna/Pool/ABACA/Kyodo News Images)